FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120079847> ?p ?o ?g. }

• W3120079847 endingPage "201" @default.
• W3120079847 startingPage "194" @default.
• W3120079847 abstract "Abstract Background To evaluate the possible major adverse cardiovascular events (MACE) associated with second‐line hormonal therapy in patients with metastatic castration‐resistant prostate cancer (mCRPC). Methods We performed a population‐based real‐world cohort study of 4962 prostate cancer patients between 2014 and 2017 utilizing the Chang Gung Research Database of Taiwan. The second‐line hormonal therapies included enzalutamide and abiraterone acetate. The outcomes of interest were MACE, including acute coronary syndrome (ACS), ischemic stroke (IS), and heart failure (HF) events that resulted in hospitalization. Cox proportional‐hazards models with inverse probability of treatment weighting (IPTW) with propensity scores were used. Results After IPTW, 288 patients were prescribed second‐line hormonal therapy and 1575 received first‐line androgen‐deprivation therapy (ADT). Of all patients diagnosed with MACE, the event rates were 2.92% in the second‐line hormonal group and 2.22% in the first‐line ADT group. The mean follow‐up period was 9.52 months for the second‐line hormonal group. Patients who received second‐line hormonal therapy exhibited a significantly increased risk for MACE (hazard ratio [HR]: 3.15; 95% confidence interval [CI]: 2.03–4.89), ACS (HR: 4.94; 95% CI: 2.36–10.33), and HF (HR: 2.83; 95% CI: 1.53–5.25), compared with the first‐line ADT group, but a similar risk for IS was observed in both groups (HR: 1.70; 95% CI: 0.95–3.04). Conclusions The real‐world evidence study revealed increased risks for MACE in mCRPC patients receiving second‐line hormonal therapy." @default.
• W3120079847 created "2021-01-18" @default.
• W3120079847 creator A5023181868 @default.
• W3120079847 creator A5042360107 @default.
• W3120079847 creator A5043933686 @default.
• W3120079847 creator A5045415784 @default.
• W3120079847 creator A5051379277 @default.
• W3120079847 creator A5058723562 @default.
• W3120079847 creator A5075690127 @default.
• W3120079847 date "2021-01-04" @default.
• W3120079847 modified "2023-10-18" @default.
• W3120079847 title "Risk of major adverse cardiovascular events among second‐line hormonal therapy for metastatic castration‐resistant prostate cancer: A real‐world evidence study" @default.
• W3120079847 cites W2000496619 @default.
• W3120079847 cites W2004509655 @default.
• W3120079847 cites W2008549629 @default.
• W3120079847 cites W2030521036 @default.
• W3120079847 cites W2038201411 @default.
• W3120079847 cites W2085368059 @default.
• W3120079847 cites W2093954073 @default.
• W3120079847 cites W2098998490 @default.
• W3120079847 cites W2099276252 @default.
• W3120079847 cites W2103371988 @default.
• W3120079847 cites W2105310697 @default.
• W3120079847 cites W2110123637 @default.
• W3120079847 cites W2110534364 @default.
• W3120079847 cites W2119283349 @default.
• W3120079847 cites W2137467802 @default.
• W3120079847 cites W2148643283 @default.
• W3120079847 cites W2153275681 @default.
• W3120079847 cites W2156497356 @default.
• W3120079847 cites W2164705414 @default.
• W3120079847 cites W2166918329 @default.
• W3120079847 cites W2286563710 @default.
• W3120079847 cites W2291685772 @default.
• W3120079847 cites W2729775538 @default.
• W3120079847 cites W2767637289 @default.
• W3120079847 cites W2779121547 @default.
• W3120079847 cites W2810806599 @default.
• W3120079847 cites W2911193641 @default.
• W3120079847 cites W2912374947 @default.
• W3120079847 cites W2921117508 @default.
• W3120079847 cites W2984998740 @default.
• W3120079847 cites W3007146898 @default.
• W3120079847 cites W3082140531 @default.
• W3120079847 cites W4237882759 @default.
• W3120079847 cites W3009159291 @default.
• W3120079847 doi "https://doi.org/10.1002/pros.24096" @default.
• W3120079847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33393676" @default.
• W3120079847 hasPublicationYear "2021" @default.
• W3120079847 type Work @default.
• W3120079847 sameAs 3120079847 @default.
• W3120079847 citedByCount "5" @default.
• W3120079847 countsByYear W31200798472021 @default.
• W3120079847 countsByYear W31200798472022 @default.
• W3120079847 crossrefType "journal-article" @default.
• W3120079847 hasAuthorship W3120079847A5023181868 @default.
• W3120079847 hasAuthorship W3120079847A5042360107 @default.
• W3120079847 hasAuthorship W3120079847A5043933686 @default.
• W3120079847 hasAuthorship W3120079847A5045415784 @default.
• W3120079847 hasAuthorship W3120079847A5051379277 @default.
• W3120079847 hasAuthorship W3120079847A5058723562 @default.
• W3120079847 hasAuthorship W3120079847A5075690127 @default.
• W3120079847 hasConcept C121608353 @default.
• W3120079847 hasConcept C126322002 @default.
• W3120079847 hasConcept C143998085 @default.
• W3120079847 hasConcept C207103383 @default.
• W3120079847 hasConcept C2775832370 @default.
• W3120079847 hasConcept C2776551883 @default.
• W3120079847 hasConcept C2777899217 @default.
• W3120079847 hasConcept C2778311097 @default.
• W3120079847 hasConcept C2780192828 @default.
• W3120079847 hasConcept C2780400711 @default.
• W3120079847 hasConcept C2780739214 @default.
• W3120079847 hasConcept C2908647359 @default.
• W3120079847 hasConcept C44249647 @default.
• W3120079847 hasConcept C500558357 @default.
• W3120079847 hasConcept C50382708 @default.
• W3120079847 hasConcept C61367390 @default.
• W3120079847 hasConcept C71924100 @default.
• W3120079847 hasConcept C99454951 @default.
• W3120079847 hasConceptScore W3120079847C121608353 @default.
• W3120079847 hasConceptScore W3120079847C126322002 @default.
• W3120079847 hasConceptScore W3120079847C143998085 @default.
• W3120079847 hasConceptScore W3120079847C207103383 @default.
• W3120079847 hasConceptScore W3120079847C2775832370 @default.
• W3120079847 hasConceptScore W3120079847C2776551883 @default.
• W3120079847 hasConceptScore W3120079847C2777899217 @default.
• W3120079847 hasConceptScore W3120079847C2778311097 @default.
• W3120079847 hasConceptScore W3120079847C2780192828 @default.
• W3120079847 hasConceptScore W3120079847C2780400711 @default.
• W3120079847 hasConceptScore W3120079847C2780739214 @default.
• W3120079847 hasConceptScore W3120079847C2908647359 @default.
• W3120079847 hasConceptScore W3120079847C44249647 @default.
• W3120079847 hasConceptScore W3120079847C500558357 @default.
• W3120079847 hasConceptScore W3120079847C50382708 @default.
• W3120079847 hasConceptScore W3120079847C61367390 @default.
• W3120079847 hasConceptScore W3120079847C71924100 @default.
• W3120079847 hasConceptScore W3120079847C99454951 @default.

• next